Article
How we got here
HRSA announced a 340B rebate pilot in August 2025. Instead of buying drugs at the discounted ceiling price upfront, covered entities would have paid full price for certain drugs and then claimed rebates from manufacturers. The AHA, the Maine Hospital Association and four safety-net systems sued. A federal district court in Maine blocked the pilot on Dec. 29, and the 1st Circuit declined to stay that order on Jan. 7.
In a Feb. 5 court filing, HHS said further litigation would not be fruitful and asked the court to vacate the program and send it back to HRSA. HHS also said any future rebate program would come with fresh public notice, a comment period and an effective date at least 90 days after manufacturer approvals are announced.
The new request for information
On Feb. 13, HRSA issued a request for information asking whether to run a rebate model at all and, if so, how to design it. Comments are due March 19. The questions cover:
- Administrative, operational and financial burdens on covered entities
- How much entities rely on upfront discounts and what a rebate would do to cash flow
- Effects on patients’ access to medications
- Alternatives and ways to limit a pilot’s scope
- Interaction with other federal programs, including Medicare drug price negotiation
HRSA has asked commenters to back their answers with facts and evidence. Legal observers read the level of detail as a sign the agency intends a more careful record this time, since the court faulted the earlier effort on procedural grounds.
Why the answer matters
For many 340B hospitals, the program’s value comes from paying less at the point of purchase. A rebate structure would require them to front the full price and wait for repayment, tying up working capital and adding claims-matching and reconciliation work. The AHA has said the costs could reach hundreds of millions of dollars for hospitals serving rural and underserved communities.
The administration has clearly not abandoned the concept. The best opportunity to influence what comes next is to document real costs now, before a design is chosen.
What a strong response includes
- Cash-flow modeling. Days of cash tied up, by drug class, under plausible rebate timelines.
- Operational cost. Pharmacy and finance staff time, software and third-party administrator fees.
- Patient impact. Programs funded by 340B savings that would be at risk.
- Design guardrails. If a pilot proceeds, prompt payment standards, dispute resolution and a narrow drug list.
Archive entry for Feb 16, 2026, added Nov. 11, 2026.